CAR-T cell therapy for tough-to-treat membranous nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether specially engineered immune cells (CAR-T cells) can help people with a kidney condition called primary membranous nephropathy that has not improved with standard treatments. The goal is to see if this therapy can reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary membranous nephropathy confirmed by kidney biopsy.
- Your kidney disease is considered moderate- or high-risk and has not responded well to at least 6 months of standard therapy (steroids, cyclophosphamide, or rituximab).
- You are 18 years or older.
- Your kidney function (eGFR) is at least 30, and your other organs (liver, heart, lungs) are working well enough.
- You do not have a secondary cause for your kidney disease (like lupus, cancer, or certain infections).
- You have not had certain cell therapies before, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new type of immune cell therapy (CAR-γδ T cells) designed to treat three types of autoimmune kidney disease that haven't responded well to standard treatments. The goal is to see if this experimental therapy can reduce kidney damage and help patients avoid kidney failure.
This trial tests a new type of cell therapy (called UCAR-T) that targets two proteins on immune cells to help calm the immune system and reduce kidney damage in people with a tough-to-treat form of membranous nephropathy. It’s for patients who haven’t gotten better with standard treatments and have high levels of protein leaking into their urine.
This trial tests a new CAR-T cell treatment for children and adults with steroid-resistant nephrotic syndrome (SRNS), a kidney condition that doesn't get better with standard medicines. The goal is to see if this therapy can help improve kidney function when other treatments have failed.
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
Hear when a new Refractory Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.